Potomac Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Potomac Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.06M	Buy	1,481,742 +26,742	+2%	+$35.5K	2.39%	12
2023 Q3	$2.04M	Buy	1,455,000 +405,100	+39%	+$611K	2.6%	13
2023 Q2	$1.93M	Buy	1,049,900 +269,391	+35%	+$624K	1.98%	16
2023 Q1	$1.9M	Buy	780,509 +211,509	+37%	+$314K	1.99%	15
2022 Q4	$814K	Buy	569,000 +9,500	+2%	+$18.5K	0.95%	33
2022 Q3	$1.25M	Hold	559,500	–	–	1.43%	19
2022 Q2	$1.16M	Buy	559,500 +62,695	+13%	+$155K	1.34%	23
2022 Q1	$1.44M	Buy	496,805 +288,805	+139%	+$927K	1.24%	23
2021 Q4	$668K	Buy	+208,000	New	+$710K	0.59%	43

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Potomac Capital Management's ENZ Position: Q4 2023 in Review

Potomac Capital Management increased its Enzo Biochem, Inc. (ENZ) stake by 1.8% in Q4 2023, buying an estimated $35.5K and bringing the position to 1,481,742 shares worth $2.06M. The position accounts for 2.39% of the portfolio, ranked #12.

Potomac Capital Management first reported a position in ENZ in Q4 2021 and has held it in 9 quarters since. 46 funds tracked by Wall St. Rank hold ENZ as of Q4 2023.

Potomac Capital Management held 1,481,742 shares of Enzo Biochem, Inc. worth $2.06M as of Q4 2023.
Potomac Capital Management bought 26,742 Enzo Biochem, Inc. shares in Q4 2023, an estimated $35.5K.
Enzo Biochem, Inc. made up 2.39% of Potomac Capital Management's portfolio in Q4 2023, its #12 holding.
Potomac Capital Management first reported a position in Enzo Biochem, Inc. in Q4 2021 and has held it in 9 quarters since.
46 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2023.

Based on Potomac Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.